{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "57fce2b8-c8d6-42a6-8f88-ab5ff1ef0f6d",
   "metadata": {},
   "source": [
    "# Agentic Strategy Construction Tool\n",
    "This is to produce trade reports that can be used in the evaluation section to backtest."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "54f3d6fd-72dd-4c1e-9933-1a34794338e8",
   "metadata": {},
   "outputs": [],
   "source": [
    "import copy\n",
    "import pandas as pd\n",
    "import requesters.company_data as cd\n",
    "import agents.financial_agent as fa\n",
    "import agents.committee_agent as ca\n",
    "import importlib\n",
    "from tqdm import tqdm\n",
    "import json\n",
    "\n",
    "from utils.s3_helper import S3Helper\n",
    "from datetime import datetime\n",
    "\n",
    "import concurrent.futures\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "40fe4c19-7fa3-4e50-9fd3-1c784563a407",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<module 'agents.committee_agent' from '/project/agents/committee_agent.py'>"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "importlib.reload(fa)\n",
    "importlib.reload(ca)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "571bb9ac-6dfe-4ed9-8dc7-cf47e90267ae",
   "metadata": {},
   "source": [
    "### Collect the data needed to run the Agents\n",
    "The Agents will require financial statement datasets and news datasets in order to conduct their analysis."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d149871e-47f3-4bda-98b9-10aa13aec9ea",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get the company reports\n",
    "security_datasets = cd.SecurityData('tmp/fs', 'dow_quarterly_ltm_v3.json')\n",
    "# get the saved news datasets\n",
    "s3_helper = S3Helper('tmp/fs')\n",
    "s3_helper.get_file(filename='dow_headlines.parquet', local_filename='/tmp/dow_headlines.parquet')\n",
    "# Convert to pandas dataframe\n",
    "news_headlines = pd.read_parquet('/tmp/dow_headlines.parquet')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2261dadb-3bb3-42e3-9ee9-c2cad1bd23e5",
   "metadata": {},
   "source": [
    "### Run the Agentic Models\n",
    "Running the inference tasks across 893 date/ security combinations in 1:32h."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "67c8ff94-60c3-46d3-8378-d2fb3f69c4d4",
   "metadata": {},
   "outputs": [],
   "source": [
    "financial_agent = fa.FinancialAnalystAgent()\n",
    "committee_agent = ca.CommitteeAgent()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "e2bbb33a-04a2-46f2-b007-23b46f07a353",
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_single(security: str, as_of_date: str) -> dict:\n",
    "    \"\"\"\n",
    "    Function to run a single run of the Agent\n",
    "    \"\"\"\n",
    "    company_data = security_datasets.get_security_all_data(as_of_date, security)\n",
    "    # Time the run\n",
    "    start_time = datetime.now()\n",
    "    # Run the financial analyst agent\n",
    "    financial_report = financial_agent.run(security_data=company_data, \n",
    "                                       news_data=news_headlines, \n",
    "                                       as_of_date=as_of_date)\n",
    "    # Run the committee agent\n",
    "    committee_report = committee_agent.run(senior_analyst_report=financial_report['senior_report'],\n",
    "                                           financial_statement_analysis=financial_report['financial_report'],\n",
    "                                           security_data=company_data)\n",
    "    end_time = datetime.now()\n",
    "    decision_dict = {\n",
    "        'date': as_of_date,\n",
    "        'security': security,\n",
    "        'earning_decision': financial_report['final_output'].direction,\n",
    "        'earning_magnitude': financial_report['final_output'].magnitude,\n",
    "        'earning_confidence': financial_report['final_output'].confidence,\n",
    "        'recommendation': committee_report['results'].recommendation,\n",
    "        \n",
    "        'responses': {'financial_analyst': financial_report,\n",
    "                     'committee_report': committee_report},\n",
    "        'time': str(end_time - start_time)\n",
    "    }\n",
    "    return decision_dict\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "171f1163-d588-40d7-bc14-1e38de2f3ca1",
   "metadata": {},
   "outputs": [],
   "source": [
    "dates_and_securities = security_datasets.date_security_timeseries()\n",
    "test_security = dates_and_securities[20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "77035d29-bb7c-44dd-bd73-c0408acd1cd1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'date': '2020-01-30', 'security': 'VZ UN Equity'}"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_security"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "2c664118-ddd8-4ef6-aeae-4549c6efe6ec",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 223 ms, sys: 0 ns, total: 223 ms\n",
      "Wall time: 2min 42s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "test_output = run_single(test_security['security'],test_security['date'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f7c30730-d1a2-455e-8a7a-a3d2e96a4609",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'HOLD'"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#dict_keys(['date', 'security', 'earning_decision', 'earning_magnitude', 'earning_confidence', 'recommendation', 'responses', 'time'])\n",
    "test_output['recommendation']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "dec7f418-e6c7-47a0-ac65-639493c46a21",
   "metadata": {},
   "source": [
    "### Run the backtest"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "e3adeff4-dd47-41d2-a064-589c9cc536bb",
   "metadata": {},
   "outputs": [],
   "source": [
    "data_output = []\n",
    "def backtest(dates_and_securities):\n",
    "    # create the securities\n",
    "    progress = tqdm(total=len(dates_and_securities), position=0, leave=True)\n",
    "    with concurrent.futures.ThreadPoolExecutor(max_workers=20) as executor:\n",
    "        futures = [executor.submit(run_single, single['security'], single['date']) for single in dates_and_securities]\n",
    "        for f in concurrent.futures.as_completed(futures):\n",
    "            progress.update(n=1)\n",
    "            data_output.append(f.result())\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "a3533ae3-f9e3-407b-a968-90561b538d70",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      " 56%|█████▌    | 199/354 [1:32:09<1:11:46, 27.79s/it]\n",
      "100%|██████████| 43/43 [07:59<00:00, 11.14s/it]  \n"
     ]
    }
   ],
   "source": [
    "# Run the backtest\n",
    "backtest(dates_and_securities[909:])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "b5709c93-2091-45e2-be5b-444fb4442129",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "909"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "f036cbad-0823-4d79-a0f4-50e34be76f88",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'HOLD'"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data_output[3]['recommendation']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d7251081-c19a-4fa8-8fb9-bd92e67cedc7",
   "metadata": {},
   "outputs": [],
   "source": [
    "print(\"hello\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "79eca6d0-e791-4776-a67b-97b6fda55080",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "ed59a7b4-d3d6-407d-aee3-2341e7ba797f",
   "metadata": {},
   "source": [
    "### Save the raw output to S3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "4eb0e20d-c8db-4419-a820-e7a4702bda41",
   "metadata": {},
   "outputs": [],
   "source": [
    "data_analysis_final = copy.deepcopy(data_output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "eaafa0d7-f0ec-4d85-a46d-631b0910c777",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Some of the items are not serializable. Convert to string before JSON\n",
    "for item in data_analysis_final:\n",
    "    item['responses']['financial_analyst']['final_output'] = str(item['responses']['financial_analyst']['final_output'])\n",
    "    item['responses']['committee_report']['results'] = str(item['responses']['committee_report']['results'])\n",
    "    item['responses']['committee_report']['history'] = str(item['responses']['committee_report']['history'])\n",
    "    item['time']=str(item['time'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "52e224e8-fc98-4ca6-ac36-37ae04141177",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('/tmp/agentic_output_llama_v5.json', 'w') as f:\n",
    "    json.dump(data_analysis_final, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "19a8cb52-5f8f-4768-9715-e3e4c14209ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "s3_helper.add_file(local_filename='/tmp/agentic_output_llama_v5.json')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c6daa36b-c59a-4a4e-a40b-e59ee5bd750b",
   "metadata": {},
   "source": [
    "### Create the Trade Report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "eac0b849-f701-454c-a279-6d0b92b8ea39",
   "metadata": {},
   "outputs": [],
   "source": [
    "def trade_report_generation(data, trade_only=False) -> pd.DataFrame:\n",
    "    \"\"\"\n",
    "    Function to create the trade report to pass into the Strategy Analysis tool\n",
    "    \"\"\"\n",
    "    trade_report = []\n",
    "    if trade_only:\n",
    "        for item in data:\n",
    "            trade_report.append({'date': item['date'], \n",
    "                                 'security': item['security'], \n",
    "                                 'decision': item['recommendation'],\n",
    "                                 'confidence': item['earning_confidence']})\n",
    "    \n",
    "        return pd.DataFrame(data=trade_report)\n",
    "    else:\n",
    "        for item in data:\n",
    "            trade_report.append({'date': item['date'], \n",
    "                                 'security': item['security'], \n",
    "                                 'decision': item['recommendation'],\n",
    "                                 'confidence': item['earning_confidence'],\n",
    "                                 'earning_decision': item['earning_decision'],\n",
    "                                 'earning_magnitude': item['earning_magnitude']})\n",
    "        return trade_report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "cbf18955-f299-4791-9c4c-628c9d13b843",
   "metadata": {},
   "outputs": [],
   "source": [
    "trades = trade_report_generation(data_analysis_final)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "27511b7e-0f5b-4521-9bdc-25de895efa0e",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('Results/Agentic/trades_llama_v5.json', 'w') as f:\n",
    "    json.dump(trades, f)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "64adfb73-3c04-4e86-9750-741454806d5b",
   "metadata": {},
   "source": [
    "### Unused code"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "ef4964d6-3cee-497f-b7a4-004edd8431c5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# from utils.s3_helper import S3Helper\n",
    "\n",
    "# s3_helper = S3Helper('tmp/fs')\n",
    "# s3_helper.get_file(filename='agentic_output_llama_v3_1.json',local_filename='/tmp/agentic_output_llama_v3_1.json')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "7c0193ff-7f13-4a47-ad98-ddb39fea01f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import json\n",
    "# with open('/tmp/agentic_output_llama_v3_1.json', 'rb') as f:\n",
    "#     data_output = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "24b273b8-eb01-4abe-9762-84554273ee8a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'date': '2020-01-15', 'security': 'UNH UN Equity', 'earning_decision': 'increase', 'earning_magnitude': 'moderate', 'earning_confidence': 'moderate', 'recommendation': 'BUY', 'responses': {'financial_analyst': {'company_details': {'name': 'UnitedHealth Group Inc', 'figi_name': 'BBG000CH5208', 'sector': 'Health Care', 'sec_fs': 'Income Statement:                                                        t           t-1           t-2           t-3           t-4           t-5\\nitems                                                                                                                          \\nRevenue                                      2.421550e+11  2.396710e+11  2.358760e+11  2.313670e+11  2.262470e+11  2.198910e+11\\nSales and Services Revenues                  5.057000e+10  5.087100e+10  4.994400e+10  4.836800e+10  4.678400e+10  4.502500e+10\\nOther Revenue                                1.915850e+11  1.888000e+11  1.859320e+11  1.829990e+11  1.794630e+11  1.748660e+11\\nCost of Revenue                              1.845570e+11  1.833500e+11  1.805580e+11  1.766740e+11  1.724010e+11  1.675070e+11\\nGross Profit                                 5.759800e+10  5.632100e+10  5.531800e+10  5.469300e+10  5.384600e+10  5.238400e+10\\nOperating Expenses                           3.791300e+10  3.723400e+10  3.665500e+10  3.657000e+10  3.650200e+10  3.556000e+10\\nOther Operating Expenses                     3.519300e+10  3.459500e+10  3.411400e+10  3.408500e+10  3.407400e+10  3.319100e+10\\nOperating Income or Losses                   1.968500e+10  1.908700e+10  1.866300e+10  1.812300e+10  1.734400e+10  1.682400e+10\\nNon-Operating (Income) Loss                  1.704000e+09  1.641000e+09  1.545000e+09  1.471000e+09  1.400000e+09  1.334000e+09\\nPretax Income (Loss), Adjusted               1.798100e+10  1.744600e+10  1.711800e+10  1.665200e+10  1.594400e+10  1.549000e+10\\nIncome Tax Expense (Benefit)                 3.742000e+09  3.711000e+09  3.728000e+09  3.637000e+09  3.562000e+09  2.551000e+09\\nIncome (Loss) from Continuing Operations     1.423900e+10  1.373500e+10  1.339000e+10  1.301500e+10  1.238200e+10  1.293900e+10\\nNet Income/Net Profit (Losses)               1.383900e+10  1.333800e+10  1.298800e+10  1.261700e+10  1.198600e+10  1.256300e+10\\nNet Abnormal Losses (Gains)                  0.000000e+00  0.000000e+00  0.000000e+00  0.000000e+00  0.000000e+00 -1.197000e+09\\nBasic Weighted Average Number of Shares      9.547500e+08  9.597500e+08  9.630000e+08  9.657500e+08  9.677500e+08  9.700000e+08\\nBasic Earnings per Share                     1.450000e+01  1.392000e+01  1.350000e+01  1.307000e+01  1.239000e+01  1.294000e+01\\nBasic EPS from Continuing Operations         1.450000e+01  1.392000e+01  1.350000e+01  1.307000e+01  1.239000e+01  1.173198e+01\\nDiluted Weighted Average Shares              9.660000e+08  9.710000e+08  9.760000e+08  9.805000e+08  9.835000e+08  9.857500e+08\\nDiluted EPS                                  1.433000e+01  1.375000e+01  1.332000e+01  1.288000e+01  1.219000e+01  1.274000e+01\\nDiluted EPS from Continuing Operations, Adj  1.433000e+01  1.375000e+01  1.332000e+01  1.288000e+01  1.219000e+01  1.153198e+01\\n Balance Sheet:                                               t           t-1           t-2           t-3           t-4           t-5\\nitems                                                                                                                \\nCash, Cash Equivalents & STI       1.424500e+10  1.581800e+10  1.726900e+10  1.571000e+10  1.432400e+10  1.384900e+10\\nCash & Cash Equivalents            1.424500e+10  1.236300e+10  1.374500e+10  1.240700e+10  1.086600e+10  1.026300e+10\\nST Investments                     0.000000e+00  3.455000e+09  3.524000e+09  3.303000e+09  3.458000e+09  3.586000e+09\\nAccounts & Notes Receiv            1.182200e+10  1.096400e+10  9.741000e+09  1.282600e+10  1.138800e+10  1.099200e+10\\nOther ST Assets                    1.656700e+10  1.675900e+10  1.502800e+10  1.427900e+10  1.298000e+10  1.391300e+10\\nTotal Current Assets               4.263400e+10  4.354100e+10  4.203800e+10  4.281500e+10  3.869200e+10  3.875400e+10\\nProperty, Plant & Equip, Net       0.000000e+00  8.501000e+09  8.681000e+09  8.230000e+09  8.458000e+09  8.042000e+09\\nProperty, Plant & Equip            0.000000e+00  0.000000e+00  0.000000e+00  0.000000e+00  1.259900e+10  0.000000e+00\\nAccumulated Depreciation           0.000000e+00  0.000000e+00  0.000000e+00  0.000000e+00  4.141000e+09  0.000000e+00\\nLT Investments & Receivables       3.720900e+10  3.684000e+10  3.569600e+10  3.355300e+10  3.251000e+10  3.192900e+10\\nOther LT Assets                    9.404600e+10  8.482700e+10  8.078500e+10  7.659900e+10  7.256100e+10  7.236200e+10\\nTotal Intangible Assets            0.000000e+00  7.572600e+10  7.199900e+10  6.862400e+10  6.823500e+10  6.820100e+10\\nGoodwill                           0.000000e+00  6.520500e+10  6.200000e+10  5.937900e+10  5.891000e+10  5.870300e+10\\nOther Intangible Assets            0.000000e+00  1.052100e+10  9.999000e+09  9.245000e+09  9.325000e+09  9.498000e+09\\nMisc LT Assets                     2.997700e+10  7.547000e+09  6.312000e+09  5.086250e+09  4.029500e+09  3.841750e+09\\nTotal Noncurrent Assets            1.312550e+11  1.301680e+11  1.251620e+11  1.183820e+11  1.135290e+11  1.123330e+11\\nTotal Assets                       1.738890e+11  1.737090e+11  1.672000e+11  1.611970e+11  1.522210e+11  1.510870e+11\\nPayables & Accruals                2.169000e+10  3.950900e+10  3.803500e+10  3.803900e+10  3.659600e+10  3.884100e+10\\nAccounts Payable                   2.169000e+10  2.093900e+10  2.090700e+10  2.113900e+10  1.989100e+10  1.985000e+10\\nOther Payables & Accruals          0.000000e+00  1.857000e+10  1.712800e+10  1.690000e+10  1.670500e+10  1.899100e+10\\nST Debt                            3.870000e+09  6.585000e+09  8.196000e+09  4.399000e+09  1.973000e+09  1.500000e+09\\nST Borrowings                      3.870000e+09  6.387000e+09  7.800000e+09  3.919000e+09  1.973000e+09  1.500000e+09\\nST Operating Leases                0.000000e+00  1.980000e+08  3.960000e+08  4.800000e+08  0.000000e+00  0.000000e+00\\nOther ST Liabilities               3.622200e+10  1.654700e+10  1.609700e+10  1.649500e+10  1.464000e+10  1.603600e+10\\nDeferred Revenue                   0.000000e+00  2.500000e+09  2.019000e+09  2.530000e+09  2.396000e+09  2.388000e+09\\nMisc ST Liabilities                3.622200e+10  1.404700e+10  1.407800e+10  1.396500e+10  1.224400e+10  1.364800e+10\\nTotal Current Liabilities          6.178200e+10  6.264100e+10  6.232800e+10  5.893300e+10  5.320900e+10  5.637700e+10\\nLT Debt                            3.680800e+10  4.225900e+10  3.809500e+10  3.736000e+10  3.458100e+10  3.205300e+10\\nLT Borrowings                      3.680800e+10  3.850700e+10  3.447300e+10  3.441900e+10  3.458100e+10  3.205300e+10\\nLT Operating Leases                0.000000e+00  3.752000e+09  3.622000e+09  2.941000e+09  0.000000e+00  0.000000e+00\\nOther LT Liabilities               1.313700e+10  1.105300e+10  8.721000e+09  1.045300e+10  8.204000e+09  8.292000e+09\\nMisc LT Liabilities                1.313700e+10  8.151000e+09  5.813000e+09  7.667000e+09  5.730000e+09  5.858000e+09\\nTotal Noncurrent Liabilities       4.994500e+10  5.331200e+10  4.681600e+10  4.781300e+10  4.278500e+10  4.034500e+10\\nTotal Liabilities                  1.117270e+11  1.159530e+11  1.091440e+11  1.067460e+11  9.599400e+10  9.672200e+10\\nShare Capital & APIC               0.000000e+00  9.000000e+06  9.000000e+06  1.000000e+07  1.000000e+07  1.000000e+07\\nRetained Earnings                  0.000000e+00  5.869600e+10  5.636700e+10  5.547200e+10  5.584600e+10  5.438600e+10\\nOther Equity                       6.043600e+10 -3.709000e+09 -3.273000e+09 -3.758000e+09 -4.160000e+09 -4.386000e+09\\nEquity Before Minority Interest    6.043600e+10  5.499600e+10  5.310300e+10  5.172400e+10  5.169600e+10  5.001000e+10\\nMinority/Non Controlling Interest  1.726000e+09  2.760000e+09  4.953000e+09  2.727000e+09  4.531000e+09  4.355000e+09\\nTotal Equity                       6.216200e+10  5.775600e+10  5.805600e+10  5.445100e+10  5.622700e+10  5.436500e+10', 'headlines': ['unitedhealth agrees to buy diplomat pharmacy at discount (1)', 'unitedhealth pt raised to $279 from $257 at ubs', 'diplomat pharmacy cut to market perform at raymond james', '*diplomat pharmacy falls 19% as co. warns on debt obligations', 'unitedhealth pt raised to $366 from $291 at bernstein', '*unitedhealth acquires start-up vivify health: cnbc', '*some verizon, alabama education retiree plans switch from unh', 'unitedhealth implied volatility surges as shares rise', 'unitedhealth third quarter adjusted eps beats highest estimate', '*unitedhealth says hemsley to give up executive chair position', '*dplo: interest in whole company, businesses; in advanced talks', '*diplomat: substantial doubt about continuing as going concern', '*pulmonx: unh lifted coverage restrictions on the zephyr valve', 'unitedhealth loses two large retiree health accounts to rivals', '*unitedhealth extends intraday rise to 5.2% to 9-month high', 'diplomat pharmacy may be worth $2-$7/share in sale: baird (1)', 'health insurers gain most since 2013 as medical cost fears ease', \"*warren's new medicare plan looks similar to biden's: evercore\", 'unitedhealth pt raised to $273 from $258 at stephens', 'unitedhealth pt cut to $257 from $281 at ubs', '*diplomat: may not be able to meet covenants in credit pact', '*unitedhealth 3q adj eps $3.88, est. $3.75', \"*diplomat pharmacy `going concern' may get near-term fix: cowen\", 'unitedhealth says hemsley gives up executive chair position', '*unitedhealth ceo comments on earnings call', 'unitedhealth 2020 adjusted eps view midpoint misses est.', 'unitedhealth 2020 adjusted eps view midpoint misses est. (1)', 'unitedhealth goes ex-dividend, trades without payout', '*dplo sees fy rev. $4.9b to $5.1b, saw $4.7b to $5b, est. $4.87b', 'unitedhealth fades from high, resistance zone $272-$276', '*diplomat pharmacy sees fy loss/shr $4.81 to $4.91', 'unitedhealth implied volatility drops as shares rise', '*diplomat pharmacy may be worth $2-$7/share in sale, baird says', '*unitedhealth is said to lose two large retiree health accounts', 'unitedhealth boosts fy adjusted eps view, beats est.', 'diplomat pharmacy may be worth $2-$7/share in sale, baird says', '*unitedhealth added to goldman sachs conviction buy list', \"*diplomat: mitigation plans 'beyond our control'\", '*diplomat: continue to pursue comprehensive alternatives', 'unitedhealth implied volatility surges as shares rise', 'diplomat pharmacy cut to equal-weight at barclays; pt $3', 'diplomat pharmacy sinks to record low on debt warning (1)', '*unh sees fy rev. $242b, saw $243b to $245b, est. $242.58b', '*diplomat pharmacy 3q loss/shr $2.35', 'unitedhealth hits 52-week high at $283.04', 'n.a. health agenda: jpmorgan conference, unitedhealth earnings', '*unitedhealth 3q rev. $60.4b, est. $59.74b', 'unitedhealth raises forecast as medical costs appear to steady', 'a patient cost $12,945 a month, so unitedhealth gave him housing', '*unitedhealth 3q eps $3.67 vs. $3.24 y/y'], 'stock_prices': '\\n Historical Price:              Price\\nDate              \\n2019-01-15  256.87\\n2019-02-15  271.13\\n2019-03-15  251.40\\n2019-04-15  230.20\\n2019-05-15  236.08\\n2019-06-15  245.37\\n2019-07-15  265.96\\n2019-08-15  244.25\\n2019-09-15  233.61\\n2019-10-15  238.59\\n2019-11-15  269.40\\n2019-12-15  285.48\\n2020-01-15  296.41'}, 'financial_report': \"**Analysis of Current Profitability, Liquidity, Solvency, and Efficiency Ratios**\\n\\n1. **Gross Margin Ratio**: (Gross Profit / Revenue) = (5.759800e+10 / 2.421550e+11) = 23.8%\\n2. **Operating Margin Ratio**: (Operating Income / Revenue) = (1.968500e+10 / 2.421550e+11) = 8.1%\\n3. **Net Profit Margin Ratio**: (Net Income / Revenue) = (1.383900e+10 / 2.421550e+11) = 5.7%\\n4. **Current Ratio**: (Total Current Assets / Total Current Liabilities) = (4.263400e+10 / 6.178200e+10) = 0.69\\n5. **Debt-to-Equity Ratio**: (Total Liabilities / Total Equity) = (1.117270e+11 / 6.216200e+10) = 1.80\\n6. **Asset Turnover Ratio**: (Revenue / Total Assets) = (2.421550e+11 / 1.738890e+11) = 1.39\\n7. **Return on Equity (ROE)**: (Net Income / Total Equity) = (1.383900e+10 / 6.216200e+10) = 22.3%\\n\\n**Time-Series Analysis Across Ratios**\\n\\n* Gross Margin Ratio: increasing over the past 5 years, indicating improving profitability\\n* Operating Margin Ratio: relatively stable, with a slight increase over the past 5 years\\n* Net Profit Margin Ratio: increasing over the past 5 years, indicating improving profitability\\n* Current Ratio: decreasing over the past 5 years, indicating potential liquidity issues\\n* Debt-to-Equity Ratio: increasing over the past 5 years, indicating increasing leverage\\n* Asset Turnover Ratio: relatively stable, with a slight increase over the past 5 years\\n* Return on Equity (ROE): increasing over the past 5 years, indicating improving profitability\\n\\n**Analysis of Financial Performance**\\n\\nThe company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. However, the current ratio has been decreasing, indicating potential liquidity issues. The debt-to-equity ratio has also been increasing, indicating increasing leverage. The asset turnover ratio has been relatively stable, and the return on equity (ROE) has been increasing, indicating improving profitability.\\n\\n**Weighing Up the Positive and Negative Factors**\\n\\nPositive factors:\\n\\n* Improving profitability (increasing gross margin, operating margin, and net profit margin ratios)\\n* Increasing return on equity (ROE)\\n\\nNegative factors:\\n\\n* Potential liquidity issues (decreasing current ratio)\\n* Increasing leverage (increasing debt-to-equity ratio)\\n\\n**Final Decision**\\n\\nBased on the analysis, I expect the company's earnings to increase over the next financial period, driven by improving profitability and increasing return on equity. However, the potential liquidity issues and increasing leverage are concerns that need to be monitored. I estimate the increase in earnings to be around 5-7%.\\n\\n**Confidence Score**: 7/10\\n\\nI am moderately confident in my decision, as the analysis suggests improving profitability and increasing return on equity, but the potential liquidity issues and increasing leverage are concerns that need to be monitored.\", 'cleaned_headlines': \"Here is the list of headlines with all references to UnitedHealth Group Inc and their products removed, and replaced with the term 'blah', as well as replacing names of people with the term 'whah':\\n\\n* blah agrees to buy diplomat pharmacy at discount (1)\\n* blah pt raised to $279 from $257 at ubs\\n* diplomat pharmacy cut to market perform at raymond james\\n* diplomat pharmacy falls 19% as co. warns on debt obligations\\n* blah pt raised to $366 from $291 at bernstein\\n* blah acquires start-up vivify health: cnbc\\n* some verizon, alabama education retiree plans switch from blah\\n* blah implied volatility surges as shares rise\\n* blah third quarter adjusted eps beats highest estimate\\n* whah to give up executive chair position\\n* dplo: interest in whole company, businesses; in advanced talks\\n* diplomat: substantial doubt about continuing as going concern\\n* pulmonx: blah lifted coverage restrictions on the zephyr valve\\n* blah loses two large retiree health accounts to rivals\\n* blah extends intraday rise to 5.2% to 9-month high\\n* diplomat pharmacy may be worth $2-$7/share in sale: baird (1)\\n* health insurers gain most since 2013 as medical cost fears ease\\n* whah's new medicare plan looks similar to biden's: evercore\\n* blah pt raised to $273 from $258 at stephens\\n* blah pt cut to $257 from $281 at ubs\\n* diplomat: may not be able to meet covenants in credit pact\\n* blah 3q adj eps $3.88, est. $3.75\\n* diplomat pharmacy `going concern' may get near-term fix: cowen\\n* whah gives up executive chair position\\n* blah ceo comments on earnings call\\n* blah 2020 adjusted eps view midpoint misses est.\\n* blah 2020 adjusted eps view midpoint misses est. (1)\\n* blah goes ex-dividend, trades without payout\\n* dplo sees fy rev. $4.9b to $5.1b, saw $4.7b to $5b, est. $4.87b\\n* blah fades from high, resistance zone $272-$276\\n* diplomat pharmacy sees fy loss/shr $4.81 to $4.91\\n* blah implied volatility drops as shares rise\\n* diplomat pharmacy may be worth $2-$7/share in sale, baird says\\n* blah is said to lose two large retiree health accounts\\n* blah boosts fy adjusted eps view, beats est.\\n* diplomat pharmacy may be worth $2-$7/share in sale, baird says\\n* blah added to goldman sachs conviction buy list\\n* diplomat: mitigation plans 'beyond our control'\\n* diplomat: continue to pursue comprehensive alternatives\\n* blah implied volatility surges as shares rise\\n* diplomat pharmacy cut to equal-weight at barclays; pt $3\\n* diplomat pharmacy sinks to record low on debt warning (1)\\n* blah sees fy rev. $242b, saw $243b to $245b, est. $242.58b\\n* diplomat pharmacy 3q loss/shr $2.35\\n* blah hits 52-week high at $283.04\\n* n.a. health agenda: jpmorgan conference, blah earnings\\n* blah 3q rev. $60.4b, est. $59.74b\\n* blah raises forecast as medical costs appear to steady\\n* a patient cost $12,945 a month, so blah gave him housing\\n* blah 3q eps $3.67 vs. $3.24 y/y\", 'news_report': \"As a financial analyst, I'll start by listing the revenue drivers for the Health Care sector, which includes Blah:\\n\\n1. Premium revenue from health insurance plans\\n2. Medical cost trends (e.g., hospitalization rates, pharmaceutical costs)\\n3. Government reimbursement rates (e.g., Medicare, Medicaid)\\n4. Enrollment growth in health insurance plans\\n5. Expansion into new markets or product lines (e.g., Medicare Advantage, Medicaid managed care)\\n6. Partnerships and collaborations with healthcare providers, pharmaceutical companies, or technology firms\\n7. Investment income from invested assets (e.g., pension funds, investments in healthcare companies)\\n\\nNow, let's analyze the headlines to determine if Blah will see an increase or decrease in their earnings over the next quarter:\\n\\n**Positive indicators:**\\n\\n1. Blah's third-quarter adjusted EPS beat the highest estimate, and the company raised its forecast as medical costs appear to steady.\\n2. The company acquired Vivify Health, a start-up, which could lead to new revenue streams.\\n3. Blah was added to Goldman Sachs' Conviction Buy List, indicating a positive outlook from the investment bank.\\n4. The company's implied volatility has surged as shares rise, suggesting increased investor confidence.\\n5. Blah's 2020 adjusted EPS view midpoint was revised upward, beating estimates.\\n\\n**Negative indicators:**\\n\\n1. Blah lost two large retiree health accounts to rivals, which could lead to a decline in premium revenue.\\n2. The company's 2020 adjusted EPS view midpoint initially missed estimates, although it was later revised upward.\\n3. Diplomat Pharmacy, a company Blah is acquiring, has significant debt obligations and has warned about its ability to meet covenants in its credit pact.\\n4. Some Verizon and Alabama education retiree plans switched from Blah, which could lead to a decline in premium revenue.\\n\\n**Neutral indicators:**\\n\\n1. Blah's acquisition of Diplomat Pharmacy at a discount could be a strategic move, but it also comes with significant debt obligations.\\n2. The company's implied volatility has dropped as shares rise, which could indicate a decrease in investor uncertainty.\\n3. Blah's CEO comments on the earnings call were not explicitly positive or negative.\\n\\n**Conclusion:**\\n\\nBased on the analysis, I believe Blah will see an increase in earnings over the next quarter. The company's strong third-quarter performance, acquisition of Vivify Health, and addition to Goldman Sachs' Conviction Buy List are positive indicators. While the loss of two large retiree health accounts and Diplomat Pharmacy's debt obligations are concerns, they are likely to be offset by the company's overall growth prospects and steady medical cost trends. Therefore, I expect Blah's earnings to increase in the next quarter.\", 'senior_report': \"Based on the analysis of the financial statements and the company trends, I agree with the narrative of earnings increase. The company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. The acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although there are concerns about potential liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nTo determine if the stock is a BUY or SELL, I will use the Price-to-Earnings (P/E) ratio and the Price-to-Book (P/B) ratio.\\n\\n**Price-to-Earnings (P/E) Ratio:**\\n\\nThe P/E ratio is calculated by dividing the current stock price by the earnings per share (EPS). Based on the financial statements, the EPS for the current year is $14.50.\\n\\nAssuming a current stock price of $200 (for illustration purposes), the P/E ratio would be:\\n\\nP/E Ratio = $200 / $14.50 = 13.79\\n\\nThe industry average P/E ratio for the Health Care sector is around 15-20. Based on this, the company's P/E ratio is relatively low, indicating that the stock may be undervalued.\\n\\n**Price-to-Book (P/B) Ratio:**\\n\\nThe P/B ratio is calculated by dividing the current stock price by the book value per share. Based on the financial statements, the book value per share is:\\n\\nBook Value per Share = Total Equity / Total Shares Outstanding\\n= $6.2162 billion / 954.75 million shares\\n= $6.51 per share\\n\\nAssuming a current stock price of $200 (for illustration purposes), the P/B ratio would be:\\n\\nP/B Ratio = $200 / $6.51 = 30.72\\n\\nThe industry average P/B ratio for the Health Care sector is around 2-4. Based on this, the company's P/B ratio is relatively high, indicating that the stock may be overvalued.\\n\\n**Recommendation:**\\n\\nBased on the analysis, I recommend a BUY rating for the stock. Although the P/B ratio is high, the P/E ratio is relatively low, and the company's financial performance has been improving. Additionally, the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, investors should monitor the company's liquidity issues and increasing leverage.\\n\\n**Target Price:**\\n\\nBased on the analysis, I estimate a target price of $220-$250 per share, representing a 10-25% upside from the current price.\\n\\n**Confidence Score:**\\n\\nI am moderately confident in my decision, with a confidence score of 7/10. The analysis suggests that the company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, the potential liquidity issues and increasing leverage are concerns that need to be monitored.\", 'final_output': EarningsReportOutput(direction='increase', magnitude='moderate', reason=\"The company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. The acquisition of Vivify Health and addition to Goldman Sachs' Conviction Buy List are positive indicators. P/E ratio is relatively low at 13.79 (industry average 15-20), suggesting potential undervaluation. Recommended as a BUY with a target price of $220-$250 per share.\", confidence='moderate')}, 'committee_report': {'last_agent': 'HOLD', 'history': [HumanMessage(content='Nothing', additional_kwargs={}, response_metadata={}, id='eb3ac10c-034f-46ea-9991-76f651714356'), HumanMessage(content=\"BUY:**Recommendation: BUY**\\n\\nBased on the analysis, I recommend a BUY rating for the stock. The company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. The acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although the P/B ratio is high, the P/E ratio is relatively low, indicating that the stock may be undervalued.\\n\\n**Target Price:** $220-$250 per share, representing a 10-25% upside from the current price.\\n\\n**Confidence Score:** 7/10\\n\\nI am moderately confident in my decision, as the analysis suggests improving profitability and increasing return on equity, but the potential liquidity issues and increasing leverage are concerns that need to be monitored.\\n\\n**DCF Analysis:**\\n\\nTo estimate the intrinsic value of the stock, I will use a Discounted Cash Flow (DCF) analysis. I will use the following assumptions:\\n\\n* Discount rate: 10%\\n* Growth rate: 5-7% (based on the analysis of the company's financial performance)\\n* Terminal growth rate: 3%\\n* Terminal year: 2025\\n\\nUsing the DCF model, I estimate the intrinsic value of the stock to be around $240-$260 per share, which is higher than the current price.\\n\\n**Sensitivity Analysis:**\\n\\nTo test the sensitivity of the DCF model, I will vary the discount rate and growth rate assumptions.\\n\\n* Discount rate: 12% (instead of 10%) -> Intrinsic value: $220-$240 per share\\n* Growth rate: 3-5% (instead of 5-7%) -> Intrinsic value: $200-$220 per share\\n\\nThe results of the sensitivity analysis indicate that the intrinsic value of the stock is sensitive to changes in the discount rate and growth rate assumptions. However, the estimated intrinsic value is still higher than the current price, indicating that the stock may be undervalued.\\n\\n**Conclusion:**\\n\\nBased on the analysis, I recommend a BUY rating for the stock, with a target price of $220-$250 per share.**\", additional_kwargs={}, response_metadata={}, id='785b7b84-2f5f-4c43-a1db-aa92146b5106'), HumanMessage(content=\"SELL:**Rebuttal to the BUY Recommendation**\\n\\nAfter reviewing the analysis, I strongly disagree with the BUY recommendation. While the company's financial performance has been improving, I believe the potential liquidity issues and increasing leverage outweigh the positive factors. Furthermore, the P/B ratio is significantly higher than the industry average, indicating that the stock may be overvalued.\\n\\n**DCF Analysis**\\n\\nTo estimate the intrinsic value of the stock, I will use a Discounted Cash Flow (DCF) analysis. Assuming a 5-year growth period, a terminal growth rate of 3%, and a discount rate of 10%, I estimate the present value of the company's future cash flows to be around $180 per share. This is significantly lower than the current stock price of $200.\\n\\n**Sensitivity Analysis**\\n\\nTo test the sensitivity of the DCF model, I will vary the growth rate and discount rate. Assuming a 7% growth rate and a 12% discount rate, the estimated present value of the company's future cash flows is around $150 per share. This further supports my argument that the stock is overvalued.\\n\\n**Technical Analysis**\\n\\nReviewing the historical price data, I notice that the stock price has been trending upwards over the past year, but has recently experienced a slight correction. The Relative Strength Index (RSI) is currently around 60, indicating that the stock is not overbought. However, the Moving Average Convergence Divergence (MACD) is showing a bearish signal, indicating a potential reversal in the trend.\\n\\n**Recommendation**\\n\\nBased on the DCF analysis, sensitivity analysis, and technical analysis, I strongly recommend a SELL rating for the stock. The potential liquidity issues and increasing leverage, combined with the high P/B ratio and overvalued stock price, make it a risky investment. I estimate a target price of $180-$200 per share, representing a 10-20% downside from the current price.\\n\\n**Confidence Score**: 8/10\\n\\nI am highly confident in my decision, as the DCF analysis and sensitivity analysis support my argument that the stock is overvalued. Additionally, the technical analysis indicates a potential reversal in the trend, further supporting my SELL recommendation.\", additional_kwargs={}, response_metadata={}, id='f4bafbd0-8fe9-4c5e-8537-f248381e2ef7'), HumanMessage(content=\"HOLD:**HOLD Recommendation**\\n\\nAfter reviewing the analysis presented by the senior analyst, I agree that the company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, I have some concerns that lead me to recommend a HOLD rating for the next quarter.\\n\\n**DCF Analysis**\\n\\nUsing a discounted cash flow (DCF) model, I estimate the company's intrinsic value to be around $210-$230 per share, which is close to the current price of $200. This suggests that the stock is fairly valued, and there is limited upside potential in the short term.\\n\\n**Valuation Multiples**\\n\\nWhile the P/E ratio of 13.79 is relatively low compared to the industry average, the P/B ratio of 30.72 is high. This suggests that the stock may be overvalued based on book value, but undervalued based on earnings.\\n\\n**Financial Performance**\\n\\nThe company's financial performance has been improving, with increasing gross margin, operating margin, and net profit margin ratios. However, the current ratio has been decreasing, indicating potential liquidity issues, and the debt-to-equity ratio has been increasing, indicating increasing leverage.\\n\\n**Conclusion**\\n\\nGiven the mixed signals from the valuation multiples and the concerns about liquidity and leverage, I recommend a HOLD rating for the next quarter. While the company's financial performance has been improving, I believe that the stock is fairly valued, and there is limited upside potential in the short term. I will continue to monitor the company's performance and adjust my recommendation as necessary.\\n\\n**Target Price**\\n\\nMy target price for the stock is $210-$230 per share, which is based on my DCF analysis and valuation multiples.\\n\\n**Confidence Score**\\n\\nI am moderately confident in my decision, with a confidence score of 6/10. While I believe that the company's financial performance has been improving, I have concerns about liquidity and leverage that need to be monitored.\", additional_kwargs={}, response_metadata={}, id='c2225283-4d16-485f-9bb0-0d3e5bc3247a'), HumanMessage(content=\"BUY:**Rebuttal to the SELL Recommendation and HOLD Recommendation**\\n\\nAfter reviewing the analysis presented by the senior analyst and the rebuttals, I still agree with my previous decision to BUY the stock. While I understand the concerns about liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nThe DCF analysis presented by the SELL recommendation estimates the intrinsic value of the stock to be around $180 per share, which is significantly lower than the current stock price. However, I believe that this estimate is too conservative, as it does not take into account the company's improving financial performance and the positive indicators from the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List.\\n\\nThe HOLD recommendation presents a more balanced view, but I still believe that the stock has upside potential in the short term. The estimated intrinsic value of $210-$230 per share is close to the current price, but I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\\n\\n**Updated Target Price**\\n\\nBased on my analysis, I estimate a target price of $240-$260 per share, representing a 20-30% upside from the current price.\\n\\n**Confidence Score**\\n\\nI am moderately confident in my decision, with a confidence score of 7/10. While I understand the concerns about liquidity and leverage, I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\\n\\nTherefore, I still recommend a BUY rating for the stock.\", additional_kwargs={}, response_metadata={}, id='df48fea6-3fb3-42bb-8dde-180377555a7d'), HumanMessage(content=\"SELL:**Reconsideration of Previous SELL Recommendation**\\n\\nAfter reviewing the analysis and rebuttals, I have reconsidered my previous SELL recommendation. While I still have concerns about the potential liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nThe DCF analysis I presented earlier estimated the intrinsic value of the stock to be around $180 per share, which is significantly lower than the current stock price. However, I now believe that this estimate was too conservative, as it did not take into account the company's improving financial performance and the positive indicators from the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List.\\n\\nThe P/E ratio of 13.79 is relatively low compared to the industry average, indicating that the stock may be undervalued based on earnings. While the P/B ratio of 30.72 is high, I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\\n\\n**Updated Recommendation**\\n\\nBased on my revised analysis, I am changing my previous SELL recommendation to a BUY recommendation. I estimate a target price of $220-$250 per share, representing a 10-25% upside from the current price.\\n\\n**Confidence Score**\\n\\nI am moderately confident in my decision, with a confidence score of 7/10. While I still have concerns about liquidity and leverage, I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\", additional_kwargs={}, response_metadata={}, id='faf4304b-3811-456b-9693-401d5cc499e7'), HumanMessage(content=\"HOLD:After reviewing the analysis and rebuttals, I am changing my previous HOLD recommendation to a BUY recommendation. The company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although there are concerns about potential liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nThe P/E ratio of 13.79 is relatively low compared to the industry average, indicating that the stock may be undervalued based on earnings. While the P/B ratio of 30.72 is high, I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\\n\\nMy target price for the stock is $220-$250 per share, representing a 10-25% upside from the current price. I am moderately confident in my decision, with a confidence score of 7/10.\", additional_kwargs={}, response_metadata={}, id='8fea66c1-d2fb-4a21-844c-b46164a15a6e')], 'summary_buy': \"BUY:**Recommendation: BUY**\\n\\nBased on the analysis, I recommend a BUY rating for the stock. The company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. The acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although the P/B ratio is high, the P/E ratio is relatively low, indicating that the stock may be undervalued.\\n\\n**Target Price:** $220-$250 per share, representing a 10-25% upside from the current price.\\n\\n**Confidence Score:** 7/10\\n\\nI am moderately confident in my decision, as the analysis suggests improving profitability and increasing return on equity, but the potential liquidity issues and increasing leverage are concerns that need to be monitored.\\n\\n**DCF Analysis:**\\n\\nTo estimate the intrinsic value of the stock, I will use a Discounted Cash Flow (DCF) analysis. I will use the following assumptions:\\n\\n* Discount rate: 10%\\n* Growth rate: 5-7% (based on the analysis of the company's financial performance)\\n* Terminal growth rate: 3%\\n* Terminal year: 2025\\n\\nUsing the DCF model, I estimate the intrinsic value of the stock to be around $240-$260 per share, which is higher than the current price.\\n\\n**Sensitivity Analysis:**\\n\\nTo test the sensitivity of the DCF model, I will vary the discount rate and growth rate assumptions.\\n\\n* Discount rate: 12% (instead of 10%) -> Intrinsic value: $220-$240 per share\\n* Growth rate: 3-5% (instead of 5-7%) -> Intrinsic value: $200-$220 per share\\n\\nThe results of the sensitivity analysis indicate that the intrinsic value of the stock is sensitive to changes in the discount rate and growth rate assumptions. However, the estimated intrinsic value is still higher than the current price, indicating that the stock may be undervalued.\\n\\n**Conclusion:**\\n\\nBased on the analysis, I recommend a BUY rating for the stock, with a target price of $220-$250 per share.**\", 'summary_sell': \"SELL:**Rebuttal to the BUY Recommendation**\\n\\nAfter reviewing the analysis, I strongly disagree with the BUY recommendation. While the company's financial performance has been improving, I believe the potential liquidity issues and increasing leverage outweigh the positive factors. Furthermore, the P/B ratio is significantly higher than the industry average, indicating that the stock may be overvalued.\\n\\n**DCF Analysis**\\n\\nTo estimate the intrinsic value of the stock, I will use a Discounted Cash Flow (DCF) analysis. Assuming a 5-year growth period, a terminal growth rate of 3%, and a discount rate of 10%, I estimate the present value of the company's future cash flows to be around $180 per share. This is significantly lower than the current stock price of $200.\\n\\n**Sensitivity Analysis**\\n\\nTo test the sensitivity of the DCF model, I will vary the growth rate and discount rate. Assuming a 7% growth rate and a 12% discount rate, the estimated present value of the company's future cash flows is around $150 per share. This further supports my argument that the stock is overvalued.\\n\\n**Technical Analysis**\\n\\nReviewing the historical price data, I notice that the stock price has been trending upwards over the past year, but has recently experienced a slight correction. The Relative Strength Index (RSI) is currently around 60, indicating that the stock is not overbought. However, the Moving Average Convergence Divergence (MACD) is showing a bearish signal, indicating a potential reversal in the trend.\\n\\n**Recommendation**\\n\\nBased on the DCF analysis, sensitivity analysis, and technical analysis, I strongly recommend a SELL rating for the stock. The potential liquidity issues and increasing leverage, combined with the high P/B ratio and overvalued stock price, make it a risky investment. I estimate a target price of $180-$200 per share, representing a 10-20% downside from the current price.\\n\\n**Confidence Score**: 8/10\\n\\nI am highly confident in my decision, as the DCF analysis and sensitivity analysis support my argument that the stock is overvalued. Additionally, the technical analysis indicates a potential reversal in the trend, further supporting my SELL recommendation.\", 'summary_hold': \"HOLD:**HOLD Recommendation**\\n\\nAfter reviewing the analysis presented by the senior analyst, I agree that the company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, I have some concerns that lead me to recommend a HOLD rating for the next quarter.\\n\\n**DCF Analysis**\\n\\nUsing a discounted cash flow (DCF) model, I estimate the company's intrinsic value to be around $210-$230 per share, which is close to the current price of $200. This suggests that the stock is fairly valued, and there is limited upside potential in the short term.\\n\\n**Valuation Multiples**\\n\\nWhile the P/E ratio of 13.79 is relatively low compared to the industry average, the P/B ratio of 30.72 is high. This suggests that the stock may be overvalued based on book value, but undervalued based on earnings.\\n\\n**Financial Performance**\\n\\nThe company's financial performance has been improving, with increasing gross margin, operating margin, and net profit margin ratios. However, the current ratio has been decreasing, indicating potential liquidity issues, and the debt-to-equity ratio has been increasing, indicating increasing leverage.\\n\\n**Conclusion**\\n\\nGiven the mixed signals from the valuation multiples and the concerns about liquidity and leverage, I recommend a HOLD rating for the next quarter. While the company's financial performance has been improving, I believe that the stock is fairly valued, and there is limited upside potential in the short term. I will continue to monitor the company's performance and adjust my recommendation as necessary.\\n\\n**Target Price**\\n\\nMy target price for the stock is $210-$230 per share, which is based on my DCF analysis and valuation multiples.\\n\\n**Confidence Score**\\n\\nI am moderately confident in my decision, with a confidence score of 6/10. While I believe that the company's financial performance has been improving, I have concerns about liquidity and leverage that need to be monitored.\", 'current_response': \"HOLD:After reviewing the analysis and rebuttals, I am changing my previous HOLD recommendation to a BUY recommendation. The company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although there are concerns about potential liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nThe P/E ratio of 13.79 is relatively low compared to the industry average, indicating that the stock may be undervalued based on earnings. While the P/B ratio of 30.72 is high, I believe that the company's growth prospects and the positive indicators from the acquisition and the Conviction Buy List will drive the stock price higher.\\n\\nMy target price for the stock is $220-$250 per share, representing a 10-25% upside from the current price. I am moderately confident in my decision, with a confidence score of 7/10.\", 'count': 6, 'results': Recommendation(recommendation='BUY', reason=\"The investment committee has reached a unanimous decision to BUY the security. All three analysts have voted to BUY, and the senior analyst report supports this decision. The company shows improving financial performance over the past 5 years with increasing margins, positive indicators from the Vivify Health acquisition, and inclusion in Goldman Sachs' Conviction Buy List. While there are concerns about potential liquidity issues and increasing leverage, the committee believes the company's growth prospects and steady medical cost trends will offset these concerns. The P/E ratio of 13.79 is below industry average (15-20), suggesting the stock may be undervalued based on earnings, despite a high P/B ratio. The target price range is $220-$250 per share, representing a 10-25% upside potential.\", confidence='High'), 'consensus': {'BUY': 'BUY', 'SELL': 'BUY', 'HOLD': 'BUY'}, 'senior_analyst_report': \"Based on the analysis of the financial statements and the company trends, I agree with the narrative of earnings increase. The company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. The acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. Although there are concerns about potential liquidity issues and increasing leverage, I believe that the company's overall growth prospects and steady medical cost trends will offset these concerns.\\n\\nTo determine if the stock is a BUY or SELL, I will use the Price-to-Earnings (P/E) ratio and the Price-to-Book (P/B) ratio.\\n\\n**Price-to-Earnings (P/E) Ratio:**\\n\\nThe P/E ratio is calculated by dividing the current stock price by the earnings per share (EPS). Based on the financial statements, the EPS for the current year is $14.50.\\n\\nAssuming a current stock price of $200 (for illustration purposes), the P/E ratio would be:\\n\\nP/E Ratio = $200 / $14.50 = 13.79\\n\\nThe industry average P/E ratio for the Health Care sector is around 15-20. Based on this, the company's P/E ratio is relatively low, indicating that the stock may be undervalued.\\n\\n**Price-to-Book (P/B) Ratio:**\\n\\nThe P/B ratio is calculated by dividing the current stock price by the book value per share. Based on the financial statements, the book value per share is:\\n\\nBook Value per Share = Total Equity / Total Shares Outstanding\\n= $6.2162 billion / 954.75 million shares\\n= $6.51 per share\\n\\nAssuming a current stock price of $200 (for illustration purposes), the P/B ratio would be:\\n\\nP/B Ratio = $200 / $6.51 = 30.72\\n\\nThe industry average P/B ratio for the Health Care sector is around 2-4. Based on this, the company's P/B ratio is relatively high, indicating that the stock may be overvalued.\\n\\n**Recommendation:**\\n\\nBased on the analysis, I recommend a BUY rating for the stock. Although the P/B ratio is high, the P/E ratio is relatively low, and the company's financial performance has been improving. Additionally, the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, investors should monitor the company's liquidity issues and increasing leverage.\\n\\n**Target Price:**\\n\\nBased on the analysis, I estimate a target price of $220-$250 per share, representing a 10-25% upside from the current price.\\n\\n**Confidence Score:**\\n\\nI am moderately confident in my decision, with a confidence score of 7/10. The analysis suggests that the company's financial performance has been improving, and the acquisition of Vivify Health and the addition to Goldman Sachs' Conviction Buy List are positive indicators. However, the potential liquidity issues and increasing leverage are concerns that need to be monitored.\", 'financial_statement_analysis': \"**Analysis of Current Profitability, Liquidity, Solvency, and Efficiency Ratios**\\n\\n1. **Gross Margin Ratio**: (Gross Profit / Revenue) = (5.759800e+10 / 2.421550e+11) = 23.8%\\n2. **Operating Margin Ratio**: (Operating Income / Revenue) = (1.968500e+10 / 2.421550e+11) = 8.1%\\n3. **Net Profit Margin Ratio**: (Net Income / Revenue) = (1.383900e+10 / 2.421550e+11) = 5.7%\\n4. **Current Ratio**: (Total Current Assets / Total Current Liabilities) = (4.263400e+10 / 6.178200e+10) = 0.69\\n5. **Debt-to-Equity Ratio**: (Total Liabilities / Total Equity) = (1.117270e+11 / 6.216200e+10) = 1.80\\n6. **Asset Turnover Ratio**: (Revenue / Total Assets) = (2.421550e+11 / 1.738890e+11) = 1.39\\n7. **Return on Equity (ROE)**: (Net Income / Total Equity) = (1.383900e+10 / 6.216200e+10) = 22.3%\\n\\n**Time-Series Analysis Across Ratios**\\n\\n* Gross Margin Ratio: increasing over the past 5 years, indicating improving profitability\\n* Operating Margin Ratio: relatively stable, with a slight increase over the past 5 years\\n* Net Profit Margin Ratio: increasing over the past 5 years, indicating improving profitability\\n* Current Ratio: decreasing over the past 5 years, indicating potential liquidity issues\\n* Debt-to-Equity Ratio: increasing over the past 5 years, indicating increasing leverage\\n* Asset Turnover Ratio: relatively stable, with a slight increase over the past 5 years\\n* Return on Equity (ROE): increasing over the past 5 years, indicating improving profitability\\n\\n**Analysis of Financial Performance**\\n\\nThe company's financial performance has been improving over the past 5 years, with increasing gross margin, operating margin, and net profit margin ratios. However, the current ratio has been decreasing, indicating potential liquidity issues. The debt-to-equity ratio has also been increasing, indicating increasing leverage. The asset turnover ratio has been relatively stable, and the return on equity (ROE) has been increasing, indicating improving profitability.\\n\\n**Weighing Up the Positive and Negative Factors**\\n\\nPositive factors:\\n\\n* Improving profitability (increasing gross margin, operating margin, and net profit margin ratios)\\n* Increasing return on equity (ROE)\\n\\nNegative factors:\\n\\n* Potential liquidity issues (decreasing current ratio)\\n* Increasing leverage (increasing debt-to-equity ratio)\\n\\n**Final Decision**\\n\\nBased on the analysis, I expect the company's earnings to increase over the next financial period, driven by improving profitability and increasing return on equity. However, the potential liquidity issues and increasing leverage are concerns that need to be monitored. I estimate the increase in earnings to be around 5-7%.\\n\\n**Confidence Score**: 7/10\\n\\nI am moderately confident in my decision, as the analysis suggests improving profitability and increasing return on equity, but the potential liquidity issues and increasing leverage are concerns that need to be monitored.\", 'sector': 'Health Care', 'stock_prices': '\\n Historical Price:              Price\\nDate              \\n2019-01-15  256.87\\n2019-02-15  271.13\\n2019-03-15  251.40\\n2019-04-15  230.20\\n2019-05-15  236.08\\n2019-06-15  245.37\\n2019-07-15  265.96\\n2019-08-15  244.25\\n2019-09-15  233.61\\n2019-10-15  238.59\\n2019-11-15  269.40\\n2019-12-15  285.48\\n2020-01-15  296.41'}}, 'time': '0:02:40.119467'}\n"
     ]
    }
   ],
   "source": [
    "# print(data_output[1])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "2d61da3b-6900-414d-a885-e00c5af1a6d1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "893"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_analysis_final)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "11609520-1744-44b8-ba05-548714209ef3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "219"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data_output)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Bloomberg Lab Python 3",
   "language": "python",
   "name": "remote-jupyterpython"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
